Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||I-CBP112 + JQ1|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|I-CBP112||I-CBP112 is a small molecule that selectively inhibits the bromodomains of CREBBP and EP300, potentially resulting in decreased tumor cell growth (PMID: 26552700, PMID: 27673482).|
|JQ1||BET Inhibitor (Pan) 27||JQ1 is a BET bromodomain inhibitor with greatest specificity towards BRD4, resulting in decreased Myc expression, increased cell death, reduced macrophage immunosuppression, and inhibition of tumor growth (PMID: 24231268, PMID: 31018997, PMID: 30906568).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|KMT2A rearrange||leukemia||predicted - sensitive||I-CBP112 + JQ1||Preclinical||Actionable||In a preclinical study, I-CBP112 sensitized leukemia cells harboring KMT2A fusions to JQ1, resulting in decreased cell growth in culture (PMID: 26552700).||26552700|
|RUNX1 - RUNX1T1||leukemia||sensitive||I-CBP112 + JQ1||Preclinical||Actionable||In a preclinical study, the combination of I-CBP112 and JQ1 worked synergistically to inhibit growth of leukemia cells harboring a RUNX1-RUNX1T1 (AML1-ETO) fusion in culture (PMID: 26552700)||26552700|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|